Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis

NCT00332696 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Peritoneal Neoplasms
Intestinal Obstruction
Carcinomatosis

Interventions

DRUG: Octreotide LAR
DRUG: Octreotide (Immediate release)
DRUG: methylprednisolone
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals